发明授权
- 专利标题： Antibody targeting osteoclast-related protein Siglec-15
- 专利标题（中）： 抗体靶向破骨细胞相关蛋白Siglec-15
-
申请号： US13877779申请日： 2011-10-04
-
公开(公告)号： US09114131B2公开(公告)日： 2015-08-25
- 发明人: Ichiro Watanabe , Yoshiharu Hiruma , Eisuke Tsuda , Tatsuji Matsuoka , Toshiaki Ohtsuka , Tohru Takahashi , Toshinori Agatsuma , Sandra Miller , Robert Mühlbacher , Kathrin-Ladetzki Baehs , Steffen Runz , Ulrike Schubert , Ingrid Schuster , Dirk Ponsel
- 申请人： Ichiro Watanabe , Yoshiharu Hiruma , Eisuke Tsuda , Tatsuji Matsuoka , Toshiaki Ohtsuka , Tohru Takahashi , Toshinori Agatsuma , Sandra Miller , Robert Mühlbacher , Kathrin-Ladetzki Baehs , Steffen Runz , Ulrike Schubert , Ingrid Schuster , Dirk Ponsel
- 申请人地址： JP Tokyo
- 专利权人： Daiichi Sankyo Company, Limited
- 当前专利权人： Daiichi Sankyo Company, Limited
- 当前专利权人地址： JP Tokyo
- 代理机构： Foley & Lardner LLP
- 优先权： EP10251744 20101005
- 国际申请： PCT/EP2011/005219 WO 20111004
- 国际公布： WO2012/045481 WO 20120412
- 主分类号： A61K39/00
- IPC分类号： A61K39/00 ; A61K39/395 ; C07K16/00 ; C07K16/22 ; C12N5/10 ; C12N15/11 ; C12N15/63 ; C07K16/28 ; A61K45/06
摘要：
An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.
公开/授权文献
- US20130280276A1 ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN SIGLEC-15 公开/授权日：2013-10-24
信息查询
